Panel nixes Merck challenge to Sanofi's Nasacort ad claims; Wales MS patients win access to Bayer drug;

> A national panel has nixed a Merck ($MRK) challenge to advertising claims by Sanofi's ($SNY) Chattem over the company's newly launched Nasacort allergy nasal spray. Story

> Multiple sclerosis patients in Wales have won access to Bayer's Sativex. Report

> Basilea Pharmaceutica has appointed David Veitch as its chief commercial officer. Release

> The FDA is seeking a new director for the Center for Drug Evaluation and Research's Office of Medical Policy, which oversees the Office of Prescription Drug Promotion. More

> A judge has side with Depomed in its patent litigation suit against Actavis ($ACT), whose generic of Depomed's Gralise will now be delayed until 2024. Release

> India's Organization of Pharmaceutical Producers of India is asking the Department of Pharmaceuticals to make its Uniform Code of Pharmaceutical Marketing Practices a statutory code. More

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.